Correspondence to “Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India”

Abstract

Dear Editor,After reviewing the article by Sanak et al, 1 we have gained valuable insights into the usage of tofacitinib in India. Tofacitinib, a Janus kinase (JAK) inhibitor, plays a crucial role in various immune system signaling pathways and has recently become a generic medication for spondyloarthritis (SpA) in India. 2 As clinical trials are conducted in countries with diverse economic, political, and epidemiological conditions, our understanding of tofacitinib continues to expand.